DANNOAC- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501912-32-00

Enrollment

16340

Registered

2022-11-14

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation (and atrial flutter), deep vein trombosis and pulmonary embolism

Brief summary

DANNOAC-AF: A composite endpoint of stroke, myocardial infarction, thromboembolic event or all-cause death. DANNOAC-VTE: A composite endpoint of new venous thromboembolism or all-cause death.

Detailed description

Individual endpoints of the primary endpoint.

Interventions

DRUGDABIGATRAN ETEXILATE

DRUGAPIXABAN

DRUGRIVAROXABAN

DRUGEDOXABAN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
DANNOAC-AF: A composite endpoint of stroke, myocardial infarction, thromboembolic event or all-cause death. DANNOAC-VTE: A composite endpoint of new venous thromboembolism or all-cause death.	—

Secondary

Measure	Time frame
Individual endpoints of the primary endpoint.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026